Updated:
Ainos
Ainos trades on Nasdaq as a clinical-stage digital health company with its VELDONA interferon pipeline and AI Nose VOC-sensing diagnostics platform.
Ainos
Ainos was founded in 1984 as a semiconductor manufacturer in Taiwan, operating under the name Taiwan Semiconductor Corporation before an identity shift toward biotechnology and digital health under current Chairman and CEO Chun-Hsien Tsai. The company retains a thin semiconductor licensing tail tied to legacy cartridge reader and circuit design intellectual property, but has materially restructured its balance sheet and R&D agenda around low-dose oral interferon and VOC-sensing platforms since the early 2010s. The firm's clinical pipeline is anchored by VELDONA, a formulation of low-dose human interferon alpha. Lead indications include mild COVID-19, seasonal influenza, and Sjögren's syndrome — an autoimmune disorder with no FDA-approved disease-modifying therapy. In parallel, Ainos develops the AI Nose platform, a component-level VOC detection system designed for non-invasive point-of-care diagnostics, including a digital pen-form factor for sexually transmitted infection screening. Ainos reports collaboration with Taiwan's Industrial Technology Research Institute and has conducted clinical studies at Taipei Medical University Hospital. Ainos trades on the Nasdaq Capital Market under ticker AIMD, with a market capitalization that has fluctuated below $50 million since its 2021 IPO. The company operates out of San Diego, California, with a subsidiary presence in Taipei, Taiwan. Its board includes both independent directors and legacy semiconductor-industry executives. In June 2024, the company announced a registered direct offering and concurrent private placement priced at-the-market to raise working capital for its clinical programs. Unlike a standard biotech, Ainos carries a legacy hardware business that generates modest, intermittent licensing revenue — creating a capital structure more common among deep-tech spinoffs than pure-play drug developers. The firm's dual identity as a Nasdaq-listed nano-cap and cross-border entity with Taiwanese regulatory relationships gives it a clinical development pathway that peers operating solely in the U.S. trial system do not replicate.
General information
Firm type
other
Year founded
1984
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Principals
Chun-Hsien Tsai
Chairman, President & CEO
Sector focus
Frequently asked questions
What is Ainos's lead drug candidate and what does it target?
Ainos's lead pipeline platform is VELDONA, a proprietary low-dose oral formulation of human interferon alpha. The firm is investigating it for indications including mild COVID-19, seasonal influenza, and Sjögren's syndrome. Two Phase 2 clinical trials in Taiwan have evaluated VELDONA for influenza and Sjögren's, respectively. No NDA or BLA filing date has been publicly disclosed as of early 2025.
How does the legacy semiconductor business affect Ainos's valuation and operations?
Ainos retains a thin semiconductor intellectual property portfolio related to cartridge reader circuits and legacy IC designs, which it licenses to third parties. The revenue is small and intermittent, and does not subsidize clinical operations meaningfully. The legacy business does, however, provide a modest patent portfolio and a corporate lineage that can affect how the company is categorized by index providers and some institutional investors.
Where are Ainos's clinical trials conducted?
Ainos has focused its early clinical development program in Taiwan, leveraging regulatory relationships and cost efficiencies that differ materially from a U.S.-first development strategy. The company has conducted studies at Taipei Medical University Hospital and has referenced collaboration with Taiwan's Industrial Technology Research Institute. As a foreign private issuer listed on Nasdaq, Ainos files with the SEC but operates principally through its Taiwan-based subsidiary for clinical execution.
What is the AI Nose platform and how far along is it?
The AI Nose platform is a software-hardware system that uses MEMS-based gas sensor arrays and machine-learning algorithms to identify volatile organic compounds in human breath or other samples. The company has demonstrated prototype form factors including a digital pen for point-of-care screening, with an initial application aimed at sexually transmitted infection detection. The platform is pre-commercial, with no PMA or 510(k) clearance announced.
How does Ainos fund its operations given its market capitalization?
Ainos has funded operations through a combination of at-the-market equity offerings, registered direct placements, and legacy licensing revenue. In June 2024, the firm priced a registered direct offering and concurrent private placement. The company's low market capitalization limits its access to traditional biotech institutional debt, making periodic dilutive equity raises a recurring feature of its financing profile.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: